Ovid Therapeutics Inc. OVID
Ovid is a biopharmaceutical company that is dedicated to developing small molecule medicines for brain disorders with significant unmet need. These potential medicines targeting the central nervous system ("CNS") are designed to potentially halt the course of brain disease by quelling neuronal hyperexcitation and alleviating the most impactful patient symptoms. We seek to address fundamental biological targets in the brain that are implicated in neuronal hyperexcitability, such as neurotransmitters and dysregulated ion channels. By mitigating excessive neuronal hyperexcitation with differentiated medicines, we believe we can unlock substantial scientific, therapeutic and commercial opportunities across a range of neurological and psychiatric conditions that have few therapeutic options today, both impacting patients' lives and creating long-term stockholder value.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $7.3M | $566.0K | $392.0K | $1.5M | $208.4M | $12.6M | — | — | — | — |
| R&D | $25.6M | $36.8M | $28.6M | $24.6M | $46.9M | $63.4M | $42.2M | $33.8M | $50.0M | $9.6M |
| SG&A | $24.1M | $25.7M | $31.1M | $32.4M | $37.2M | $30.6M | $19.3M | $19.1M | $15.0M | $12.9M |
| Total operating expenses | $49.7M | $62.5M | $59.7M | $57.1M | $84.2M | $94.0M | $61.4M | $52.9M | $65.0M | $22.5M |
| Operating income | -$42.4M | -$61.9M | -$59.3M | -$55.5M | $124.2M | -$81.4M | -$61.4M | -$52.9M | -$65.0M | -$22.5M |
| Pre-tax income | -$17.4M | -$26.4M | -$52.3M | -$54.2M | $124.2M | -$81.0M | -$60.5M | -$52.0M | -$64.8M | — |
| Income tax | $0 | $0 | $0 | $0 | $1.3M | $0 | $0 | $0 | $0 | — |
| Net income | -$17.4M | -$26.4M | -$52.3M | -$54.2M | $122.8M | -$81.0M | -$60.5M | -$52.0M | -$64.8M | -$22.4M |
| EPS, basic | — | — | -0.74 | -0.77 | 1.78 | -1.39 | — | — | — | — |
| EPS, diluted | — | — | -0.74 | -0.77 | 1.76 | -1.39 | — | -2.11 | -3.35 | -2.28 |
| Shares, diluted (wtd. avg.) | — | — | $70.6M | $70.4M | $68.1M | $58.5M | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $13.2M | $26.3M | $29.0M | $46.8M | $189.7M | $72.0M | $41.9M | $36.5M | $87.1M | $51.9M |
| Short-term investments | $56.5M | $26.8M | $78.8M | $84.1M | $0 | — | $34.8M | $5.0M | — | — |
| Total current assets | $74.4M | $55.9M | $109.6M | $131.4M | $190.5M | $74.8M | $79.8M | $44.3M | $88.6M | $52.4M |
| Property, plant and equipment | $252.0K | $433.0K | $769.0K | $1.1M | $242.8K | $135.6K | $68.4K | $69.9K | $51.8K | $43.6K |
| Other intangibles | $0 | $100.0K | $200.0K | $222.1K | $164.1K | $319.0K | $467.0K | $392.0K | $124.2K | $110.1K |
| Total assets | $150.9M | $92.2M | $144.0M | $155.3M | $194.5M | $75.9M | $80.8M | $47.6M | $89.5M | $53.0M |
| Accounts payable | $2.0M | $3.2M | $3.7M | $2.0M | $7.1M | $5.4M | $3.3M | $3.8M | $2.0M | $857.2K |
| Total current liabilities | $8.3M | $10.5M | $11.5M | $7.0M | $14.8M | $22.1M | $10.5M | $8.8M | $6.0M | $3.7M |
| Total liabilities | $20.3M | $23.9M | $56.2M | $23.0M | $14.8M | $32.3M | $10.8M | $8.8M | — | — |
| Retained earnings | -$321.7M | -$304.3M | -$277.9M | -$225.5M | -$171.4M | -$294.2M | -$213.2M | -$152.7M | -$100.7M | -$35.9M |
| Total equity | $130.7M | $68.2M | $87.8M | $132.3M | $179.7M | $43.6M | $70.0M | $38.8M | $83.4M | $49.3M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$38.3M | -$56.0M | -$45.8M | -$55.2M | $118.6M | -$51.6M | -$51.1M | -$45.6M | -$31.5M | -$17.8M |
| Depreciation and amortisation | $273.0K | $613.0K | $568.0K | $512.5K | $237.1K | $306.8K | $255.0K | $141.7K | $80.3K | $56.5K |
| Stock-based compensation | $4.8M | $6.3M | $7.3M | $6.6M | $5.1M | $7.5M | $5.2M | $7.1M | $6.4M | $3.6M |
| Capital expenditure | $0 | $71.0K | $40.0K | $1.2M | $184.0K | $127.2K | $57.2K | $33.9K | $38.9K | $30.4K |
| Investing cash flow | -$49.9M | $54.6M | -$2.6M | -$87.9M | -$1.8M | $34.6M | -$30.0M | -$5.4M | -$47.4K | -$189.0K |
| Financing cash flow | $75.2M | $622.0K | $30.5M | $180.7K | $904.1K | $47.1M | $86.5M | $286.1K | $66.7M | -$13.7K |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001628280-26-027621.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |